Abstract
Positron Emission Tomography (PET) is an imaging modality which can determine biochemical and physiological processes in vivo in a quantitative way by using radiopharmaceuticals labeled with positron emitting radionuclides as 11C, 13N, 15O and 18F and by measuring the annihilation radiation using a coincidence technique. This includes also measurement of the pharmacokinetics of labeled drugs and the assessment of the effects of drugs on metabolism. Because only very low amounts of the radiolabeled drug have to be administered, far below toxicity levels, human studies can be carried out even before the drug is entered in Phase I. Such studies can provide cost-effective predictive toxicology data and information on the metabolism and mode of action of drugs. PET is also very useful to study the metabolic consequences of gene expression or gene defects. In the last decade many genetically engineered small animal models have been developed. The study of these animals with high resolution small animal PET cameras provides new opportunities in drug development. Especially valuable is the contribution of PET to bridge the gap between molecular biology, understanding of pathology and to the design of a new generation of drugs.
Current Pharmaceutical Design
Title: Positron Emission Tomography in Drug Development and Drug Evaluation
Volume: 6 Issue: 16
Author(s): A. M. J. Paans and W. Vaalburg
Affiliation:
Abstract: Positron Emission Tomography (PET) is an imaging modality which can determine biochemical and physiological processes in vivo in a quantitative way by using radiopharmaceuticals labeled with positron emitting radionuclides as 11C, 13N, 15O and 18F and by measuring the annihilation radiation using a coincidence technique. This includes also measurement of the pharmacokinetics of labeled drugs and the assessment of the effects of drugs on metabolism. Because only very low amounts of the radiolabeled drug have to be administered, far below toxicity levels, human studies can be carried out even before the drug is entered in Phase I. Such studies can provide cost-effective predictive toxicology data and information on the metabolism and mode of action of drugs. PET is also very useful to study the metabolic consequences of gene expression or gene defects. In the last decade many genetically engineered small animal models have been developed. The study of these animals with high resolution small animal PET cameras provides new opportunities in drug development. Especially valuable is the contribution of PET to bridge the gap between molecular biology, understanding of pathology and to the design of a new generation of drugs.
Export Options
About this article
Cite this article as:
J. Paans M. A. and Vaalburg W., Positron Emission Tomography in Drug Development and Drug Evaluation, Current Pharmaceutical Design 2000; 6 (16) . https://dx.doi.org/10.2174/1381612003398906
DOI https://dx.doi.org/10.2174/1381612003398906 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Solid Lipid Nanoparticles: Promising Therapeutic Nanocarriers for Drug Delivery
Current Drug Delivery SUBJECT INDEX TO VOLUME 1
Current Protein & Peptide Science Gene Therapy Strategies to Prevent Autoimmune Disorders
Current Gene Therapy Recent Applications of Peanut Phytoalexins
Recent Patents on Food, Nutrition & Agriculture Growth Differentiation Factor-15 as a Biomarker of Obese Pre-diabetes and Type 2 Diabetes Mellitus in Indian Subjects: A Case-control Study
Current Diabetes Reviews Characterization of the Active Components of the Multimerized sTNFRII-Adiponectin Fusion Protein Showing Both TNFα-Antagonizing and Glucose Uptake-Promoting Activities
Endocrine, Metabolic & Immune Disorders - Drug Targets Individual Cell Longevity, ‘Life’s Timekeeper’, and Metazoan Evolution
Current Aging Science Biological Nitration of Arachidonic Acid
Current Vascular Pharmacology Smart Mesoporous Silica Nanocarriers for Antitumoral Therapy
Current Topics in Medicinal Chemistry Natural Products as Aromatase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Physiology of Islet Engraftment
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) LCHAD and MTP Deficiencies - Two Disorders of Mitochondrial Fatty Acid β-Oxidation with Unusual Features
Current Pediatric Reviews Early Pathogenesis of Atherosclerosis: The Childhood Obesity
Current Pharmaceutical Design Management of Obesity
Current Respiratory Medicine Reviews A Critical Review of Bioactive Food Components, and of their Functional Mechanisms, Biological Effects and Health Outcomes
Current Pharmaceutical Design Human postnatal Mesenchymal Stem Cell Derived Islets as a Model for Diabetes Research
Current Diabetes Reviews RNA Silencing: Recent Developments on miRNAs
Recent Patents on DNA & Gene Sequences Early Development of Sea Urchin P.lividus Under Static (6 mT) and Pulsed Magnetic Fields (15 and 72 Hz)
Current Chemical Biology Structures Behind the Amyloid Aggregation of α-Synuclein: An NMR based Approach
Current Protein & Peptide Science Editorial (Thematic Issue: Current Advances in Biochemistry, Medicinal Chemistry and Drug Development Strategies for Age-Related Neurodegenerative Diseases)
Current Topics in Medicinal Chemistry